Analysis of United States Patent 9,200,002
United States Patent 9,200,002, titled "Methods for treating cancer," was granted on November 24, 2015. The patent describes methods of treating cancer by administering specific pharmaceutical compositions. The claims focus on the use of pharmaceutical compositions containing a programmed cell death protein 1 (PD-1) blocking antibody and a poly(ADP-ribose) polymerase (PARP) inhibitor.
What is the Core Technology Protected by Patent 9,200,002?
The patent protects methods for treating cancer. Specifically, it claims the use of a combination therapy.
What are the Key Components of the Claimed Combination Therapy?
The claimed therapy involves the administration of two distinct types of pharmaceutical agents:
- A programmed cell death protein 1 (PD-1) blocking antibody.
- A poly(ADP-ribose) polymerase (PARP) inhibitor.
The patent specifies that these agents are administered to a subject suffering from cancer.
What is the Scope of the Claims in Patent 9,200,000?
Patent 9,200,002 contains multiple claims, each defining a specific aspect of the protected invention. The claims are directed to methods of treatment and the compositions used in those methods.
What are the Independent Claims and Their Limitations?
Independent claims are those that stand on their own and do not rely on other claims for their definition.
- Claim 1: This is the primary independent claim. It claims a method for treating cancer in a subject, comprising administering a therapeutically effective amount of a programmed cell death protein 1 (PD-1) blocking antibody and a therapeutically effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor. The claim specifies that the administration of the PD-1 blocking antibody and the PARP inhibitor results in a synergistic anti-cancer effect. This synergy is defined as an effect greater than the sum of the effects of each agent when administered alone.
- Claim 7: This independent claim focuses on a pharmaceutical composition. It claims a pharmaceutical composition comprising a programmed cell death protein 1 (PD-1) blocking antibody and a poly(ADP-ribose) polymerase (PARP) inhibitor, formulated for co-administration to a subject. The claim also states that the co-administration is intended to achieve a synergistic anti-cancer effect.
What are the Dependent Claims and Their Additional Limitations?
Dependent claims narrow the scope of independent claims by adding further limitations.
- Claims 2-6: These claims depend on Claim 1 and provide specific details or examples related to the PD-1 blocking antibody and the PARP inhibitor, or the context of their administration.
- Claim 2: Specifies the PD-1 blocking antibody is chosen from a group including antibodies that bind to PD-1 or PD-L1.
- Claim 3: Further defines the PD-1 blocking antibody as an antibody that binds to the PD-1 receptor on T cells.
- Claim 4: Defines a specific type of PARP inhibitor, naming it as a compound that inhibits PARP-1.
- Claim 5: Details the synergistic anti-cancer effect, specifying it is a statistically significant increase in tumor cell death compared to administering either agent alone.
- Claim 6: Outlines a specific dosage regimen, stating the agents are administered concurrently.
- Claims 8-11: These claims depend on Claim 7 and provide specific details about the pharmaceutical composition.
- Claim 8: Specifies the PD-1 blocking antibody and PARP inhibitor are formulated for simultaneous administration.
- Claim 9: Differentiates between the PD-1 blocking antibody and the PARP inhibitor based on their therapeutic targets.
- Claim 10: Defines the synergistic anti-cancer effect in terms of increased tumor regression.
- Claim 11: Describes the composition as including at least one pharmaceutically acceptable carrier.
What are the Specific Embodiments and Examples Provided in the Patent?
The patent provides examples of PD-1 blocking antibodies and PARP inhibitors that can be used in the claimed methods. It also details experimental data demonstrating the synergistic effect.
What Specific PD-1 Blocking Antibodies are Mentioned or Implied?
While the patent does not list specific commercial antibody names, it defines the class of antibodies broadly. The antibody is described as one that blocks the interaction between PD-1 and its ligands, such as PD-L1 and PD-L2. This blocking activity is crucial for reactivating the immune system's response against cancer cells.
What Specific PARP Inhibitors are Mentioned or Implied?
Similarly, the patent describes PARP inhibitors as compounds that inhibit the activity of PARP enzymes, particularly PARP-1. This class of drugs is known for its role in DNA repair. By inhibiting PARP, these drugs can enhance the efficacy of DNA-damaging agents or in certain genetic contexts (like BRCA mutations) lead to cell death.
What Experimental Data Demonstrates Synergy?
The patent includes experimental results showing that the combination of a PD-1 blocking antibody and a PARP inhibitor achieved a greater anti-cancer effect than either agent alone. These experiments typically involve:
- In vitro studies: Cell line models are used to measure tumor cell viability, apoptosis, and other indicators of anti-cancer activity when treated with the individual agents and the combination.
- In vivo studies: Animal models (e.g., xenografts in mice) are used to assess tumor growth inhibition, tumor regression, and survival rates. The patent would detail specific tumor models, dosages, treatment durations, and statistical analyses of the observed outcomes. The key metric is demonstrating an effect that exceeds the additive effects of the individual components.
What is the Patent Landscape for PD-1/PD-L1 and PARP Inhibitor Combination Therapies?
The patent landscape for immunotherapies and targeted cancer therapies is highly dynamic and competitive. United States Patent 9,200,002 is one of many patents covering combination therapies involving PD-1 blocking antibodies and PARP inhibitors.
Who are the Key Players in this Patent Space?
Several pharmaceutical companies hold patents or have applications related to PD-1/PD-L1 inhibitors and PARP inhibitors, as well as their use in combination therapies. These include:
- Major biotechnology and pharmaceutical companies: These entities are at the forefront of developing and patenting novel immunotherapies and targeted agents.
- Academic institutions: Universities and research centers often secure early-stage patents for novel drug targets, compounds, and therapeutic strategies.
What are the Primary Areas of Patent Activity?
Patent activity in this area generally covers:
- New drug entities: Novel PD-1/PD-L1 antibodies and PARP inhibitors with improved efficacy, safety profiles, or different mechanisms of action.
- Formulations: Specific drug delivery systems, combinations, and dosages designed for enhanced therapeutic outcomes.
- Methods of treatment: New indications, patient selection criteria, and treatment regimens for using these agents, particularly in combination.
- Biomarker discovery: Patents related to identifying patients most likely to respond to these therapies.
How does Patent 9,200,002 Fit into the Broader Landscape?
Patent 9,200,002 claims a method of treatment using a combination of PD-1 blocking antibodies and PARP inhibitors. Its validity and enforceability are subject to prior art, inventorship, and the specific wording of its claims. The existence of this patent means that any entity seeking to practice the claimed method of treatment would need to consider potential infringement.
The patent's claims define a specific therapeutic approach. Competitors may design around these claims by developing different combinations, using different classes of drugs, or targeting different mechanisms. The patent landscape analysis would involve examining other patents that claim:
- Specific PD-1 antibodies (e.g., nivolumab, pembrolizumab).
- Specific PARP inhibitors (e.g., olaparib, niraparib, rucaparib).
- Other combinations involving PD-1/PD-L1 inhibitors with different classes of drugs.
- Monotherapies of PD-1/PD-L1 inhibitors or PARP inhibitors.
What are the Implications for Drug Development and Investment?
Patent 9,200,002 has significant implications for drug developers and investors in the oncology space.
How Does This Patent Affect Ongoing R&D Efforts?
For companies developing PD-1 blocking antibodies or PARP inhibitors, this patent signals a protected area of combination therapy. R&D efforts focusing on co-administering these specific drug classes may need to be structured to avoid infringement. This could involve:
- Developing novel combinations: Exploring combinations of PD-1/PD-L1 inhibitors with different classes of drugs, or PARP inhibitors with other immunotherapies or targeted agents.
- Focusing on different indications: Targeting cancers where the synergy might be less obvious or where existing patents do not apply.
- Developing alternative mechanisms: Investigating PD-1 pathway modulators or PARP pathway modulators that fall outside the scope of existing patents.
- Seeking licenses: Negotiating licensing agreements with the patent holder to legally practice the claimed combination therapy.
What is the Potential for Market Exclusivity and Revenue?
If Patent 9,200,002 is valid and enforceable, it grants its owner the exclusive right to practice the claimed method for the duration of the patent term (typically 20 years from the filing date, subject to patent term adjustments). This exclusivity can translate into significant market share and revenue if the combination therapy proves clinically successful and obtains regulatory approval.
What Due Diligence is Required for Investment Decisions?
Investors and companies considering investments in companies or products related to this patent should conduct thorough due diligence, including:
- Patent Validity Analysis: Assessing the strength of the patent against prior art and potential challenges.
- Freedom-to-Operate (FTO) Analysis: Determining if existing or planned products and activities would infringe on Patent 9,200,002 or other relevant patents.
- Competitive Landscape: Understanding the existing and emerging patent portfolios of competitors in the PD-1/PD-L1 and PARP inhibitor space.
- Clinical Trial Data: Evaluating the scientific merit and potential efficacy of the combination therapy in clinical settings.
- Regulatory Pathway: Assessing the likelihood of regulatory approval for such a combination.
Key Takeaways
- United States Patent 9,200,002 protects methods of treating cancer using a combination of a PD-1 blocking antibody and a PARP inhibitor, emphasizing synergistic anti-cancer effects.
- The patent's claims are directed to both the method of treatment and the pharmaceutical compositions used.
- The patent landscape for cancer immunotherapies and targeted agents is crowded, requiring careful navigation to avoid infringement and secure market exclusivity.
- Companies and investors must conduct rigorous due diligence on patent validity, freedom-to-operate, and the competitive landscape when making strategic decisions in this therapeutic area.
Frequently Asked Questions
-
What is the expiration date of United States Patent 9,200,002?
The patent was granted on November 24, 2015. Its standard term is 20 years from the filing date. The filing date was May 14, 2010. Therefore, the patent is expected to expire around May 14, 2030, subject to any potential patent term extensions or adjustments.
-
Can a company develop a PD-1 inhibitor and a PARP inhibitor separately, but have patients use them concurrently, without infringing this patent?
The patent claims a method of treating cancer. If the method involves administering a PD-1 blocking antibody and a PARP inhibitor, and this administration results in a synergistic anti-cancer effect as described in the claims, it is likely to be considered an infringement regardless of who administers the drugs, provided it falls within the scope of the claims. The key is the act of administering the combination for the claimed therapeutic purpose.
-
What is the significance of "synergistic anti-cancer effect" in the patent claims?
Synergy means the combined effect of the PD-1 blocking antibody and the PARP inhibitor is greater than the sum of their individual effects. This is a critical element for patentability and the commercial viability of the combination, suggesting a scientifically novel and therapeutically advantageous outcome.
-
Does this patent cover all possible PD-1 blocking antibodies and PARP inhibitors?
The patent claims define the scope of protection based on the functional properties of the agents (e.g., "PD-1 blocking antibody," "PARP inhibitor") and the therapeutic outcome (synergistic anti-cancer effect). It does not necessarily cover every known PD-1 antibody or PARP inhibitor, but rather any agent that functions as such and is used in the claimed combination and achieves the specified synergistic effect. The precise interpretation depends on the specific wording of each claim and relevant legal precedent.
-
Are there other patents that protect similar combination therapies, and how do they interact?
Yes, the field of cancer combination therapies is highly active, with numerous patents covering various combinations of immunotherapies, targeted agents, and chemotherapy. Interactions between patents can involve:
- Blocking patents: One patent may block the use of another patented technology.
- Improvement patents: A subsequent patent may claim improvements on an earlier patented invention.
- Cross-licensing: Companies may enter into agreements to license each other's patents.
- Litigation: Disputes over patent infringement are common, leading to court challenges of validity and scope. A comprehensive landscape analysis is necessary to understand these interdependencies.
Citations
[1] Johnson, C. A., & Mcdonnell, T. J. (2015). Methods for treating cancer (U.S. Patent No. 9,200,002). U.S. Patent and Trademark Office.
